ARTICLE SUMMARY:
Each year, 550,000 new patients develop tricuspid regurgitation, a progressive condition in which the atrioventricular valve in the right side of the heart fails. Only 1% of TR patients can undergo surgery, and they face high surgical mortality rates. Early-stage CroiValve aims to offer cardiologists one device that can treat the majority of patients, in a simple, quick, nonsurgical procedure.
Thanks to transcatheter aortic valve replacement (TAVR), many patients with heart valve disease have a new lease on life. That success is spilling over into mitral and tricuspid heart valve disease, which are both active areas of medical device innovation.
